October 21, 2005 |
Faced with the possibility of a worldwide epidemic of bird flu, the maker of the antiviral medication Tamiflu has agreed to discuss deals with generic pharmaceutical manufacturers that would increase production of the drug, which is in short supply, lawmakers said Thursday. Tamiflu is not a vaccine, but some doctors believe that if administered early it can reduce the severity of the illness and help prevent its spread. Sens. Charles E. Schumer (D-N.Y.) and Lindsey Graham (R-S.C.
November 17, 2005 |
Swiss drug maker Roche Holding said Wednesday that it had ended a dispute with U.S. biotechnology company Gilead Sciences Inc. over the manufacture of Tamiflu in what they said was a joint effort to build up inventories of the drug in the face of a threatened flu pandemic. Roche will pay Gilead $62.5 million in retroactive royalty adjustments.
June 9, 1990 |
Shareholders of biotechnology pioneer Genentech voted overwhelmingly Friday to approve the company's $2.1-billion merger with Roche Holding, a Swiss pharmaceutical giant, despite last-ditch efforts by disgruntled longtime investors to derail the plan. At the end of a rancorous annual meeting in Millbrae, south of San Francisco, the company said 97% of those voting favored the deal.
December 15, 1994 |
Consolidation in the $30-billion medical-testing business accelerated Wednesday as La Jolla-based National Health Laboratories and Swiss-owned Roche Biomedical Laboratories said they would merge into the nation's largest diagnostic laboratory chain. Company officials and analysts said the merger idea was a response to intense price pressure coming from cost-conscious managed-care firms and the federal government. The combination of the third-largest and fourth-largest U.S.
November 17, 2003 |
What is now a contest between Amgen Inc. and Johnson & Johnson over the lucrative anemia drug business could soon become a three-way race. At a medical meeting here this weekend, Swiss drug maker Roche said it was ready to begin the final round of human tests needed for government approval of Cera, its investigational anemia drug.
July 21, 2003 |
Century-old Swiss drug giant Roche Group, the parent of Hoffmann-La Roche, is returning to its roots and, potentially, its glory days. Early on, the Basel-based pharmaceutical company made a variety of novel drugs aimed at the masses, from painkillers and sleep aids to heart drugs, antibiotics and breakthrough anxiety drugs such as Valium.
July 20, 1999 |
Roche Holding's sale Monday of 20 million shares in Genentech raised $1.94 billion, a record for the biotechnology industry and the third-largest U.S. initial public offering of the year. Switzerland-based Roche sold the 16% stake in Genentech at $97 a share, near the top of an $88-$98 range set by J.P. Morgan Securities, which managed the sale. The deal produced a quick profit for the Swiss drug maker, which in June exercised an option to buy, for $82.
August 27, 2002 |
Ribapharm Inc. on Monday filed a lawsuit to prevent Swiss pharmaceutical giant Roche Holding from selling a hepatitis treatment in the United States that would compete with ribavirin, the Costa Mesa company's only product. Ribapharm, which is majority owned by ICN Pharmaceuticals Inc., filed similar suits earlier this month against Roche in the Netherlands and Germany. In its suit filed in U.S. District Court in Los Angeles, Ribapharm says it intends to enforce its U.S. patents on ribavirin.
March 5, 2008 |
Roche Holding and GlaxoSmithKline said Tuesday that they had added new labels to their prescription flu medicines that contain reports of abnormal psychiatric behavior in some patients. A warning about cases of delirium and unusual behavior had been listed previously on Roche's drug, Tamiflu. That language was strengthened to say some cases were fatal.
May 26, 1999 |
Roche Holding and BASF, which last week agreed to pay record U.S. fines totaling $725 million for conspiring to fix global vitamin prices, may also face stiff European Union fines, EU Competition Commissioner Karel Van Miert suggested. A resolution to the EU's own investigation is still months away, however, and Van Miert would not say which companies the EU may fine. Roche, Europe's fourth-biggest drug maker, agreed last week to pay $500 million--the largest U.S.